cva21
Biologicalexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00636558)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cva21
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03408587 | Phase 1 | Dec 20, 2017 | Icahn School of Medicine at Mount Sinai, Viralytics |
| NCT02824965 | Phase 1 | Jul 1, 2016 | Austin Health, Merck, Olivia Newton-John Cancer Research Institute, Viralytics |
| NCT02043665 | Phase 1 | Jan 1, 2014 | Merck, University of London, Viralytics |
| NCT00636558 | Phase 1 | Mar 1, 2008 | University of New South Wales, University of Queensland, Viralytics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viralytics | For profit | 4 | 3 | 1 | 2008 |
| Merck | For profit | 2 | 0 | 1 | 2014 |
| Austin Health | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Olivia Newton-John Cancer Research Institute | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of New South Wales | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Queensland | Academic/Hospital | 1 | 0 | 1 | 2008 |
8 organizations
Page 1 / 1